Volume 9, Issue 1 (6-2022)                   vacres 2022, 9(1): 1-7 | Back to browse issues page


XML Print


Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Abstract:   (1240 Views)
Introduction: Cancer immunotherapy is one of the effective treatment methods that provide a better quality of life with limited side effects for patients. Carcinoembryonic Antigen (CEA) can be an appropriate target for cancer immunotherapy. Methods: A lentivector expressing CEA antigen, pCDH-CEA, was constructed by cloning CEA cDNA downstream of the CMV promoter. The constructed plasmid was co-transfected with helper plasmids, into Lenti-X 293 T cells. The lentivector-containing supernatant was collected. Titers of the CEA- lentivector were estimated using the RT-PCR method. The CT26 cells were then infected by CEA- lentivector. Puromycin as a selective antibiotic was added to the culture for 2 weeks to select CEA-positive cells. The ability to produce tumors in BALB/c mice was investigated. Results: The results showed that CEA expressing lentivector plasmids and the two other helper plasmids could be transfected into Lenti-X 293T cells efficiently and packaged successfully as a pseudo-lentivector. The detection of CEA mRNA and protein expression in the 6th and 14th passages of CT26-CEA cells was confirmed in the engineered stable cell line. Tumor formation was confirmed in cell inoculated mice. Conclusion:  CT26-CEA cell line with stable expression of CEA can be used as a suitable tumor model to facilitate research on colorectal cancer in vitro and in mice models; therefore, it could be served as a valuable tool for cancer immunotherapy
Full-Text [PDF 810 kb]   (554 Downloads)    
Type of Study: Original article | Subject: Immunologic studies and animal models
Received: 2022/08/3

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.